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Abstract
Several unique biological features of HIV-1 Vpr make it a potentially powerful agent for anti-cancer therapy. First, Vpr
inhibits cell proliferation by induction of cell cycle G2 arrest. Second, it induces apoptosis through multiple mechanisms,
which could be significant as it may be able to overcome apoptotic resistance exhibited by many cancerous cells, and,
finally, Vpr selectively kills fast growing cells in a p53-independent manner. To demonstrate the potential utility of Vpr as an
anti-cancer agent, we carried out proof-of-concept studies in vitro and in vivo. Results of our preliminary studies
demonstrated that Vpr induces cell cycle G2 arrest and apoptosis in a variety of cancer types. Moreover, the same Vpr
effects could also be detected in some cancer cells that are resistant to anti-cancer drugs such as doxorubicin (DOX). To
further illustrate the potential value of Vpr in tumor growth inhibition, we adopted a DOX-resistant neuroblastoma model
by injecting SK-N-SH cells into C57BL/6N and C57BL/6J-scid/scid mice. We hypothesized that Vpr is able to block cell
proliferation and induce apoptosis regardless of the drug resistance status of the tumors. Indeed, production of Vpr via
adenoviral delivery to neuroblastoma cells caused G2 arrest and apoptosis in both drug naı ¨ve and DOX-resistant cells. In
addition, pre-infection or intratumoral injection of vpr-expressing adenoviral particles into neuroblastoma tumors in SCID
mice markedly inhibited tumor growth. Therefore, Vpr could possibly be used as a supplemental viral therapeutic agent for
selective inhibition of tumor growth in anti-cancer therapy especially when other therapies stop working.
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Introduction
Although there have been great advances in cancer treatment
over the past few decades, there still exists a number of major
hurdles that limit the use of some of these new therapies. The
obstacles that are presented include, but are not limited to, 1) serve
side-effect due to non-specific cytotoxicity of the therapies, 2)
development of drug resistance, and 3) development of tumor
resistance to apoptosis. Therefore, any anti-cancer agent that could
either avoid or override the shortcomings of some of the current
anti-cancer treatments would be of great importance for the future
design of anti-cancer therapy. Ideally, an effective anti-cancer agent
should have the following properties. It should be able to 1) block
only abnormal cell proliferation that results from loss of normal cell
cycle regulation, e.g., cellular checkpoint mutations; 2) induce
sustained cell cycle arrest that could lead to cell death or apoptosis;
3) induce specific cell killing to cancerous cells with minimal or no
effect on normal cells; 4) be able to override apoptotic resistance, a
typical feature of many cancerous cells; 5) have the cell killing effect
independentofcommononcogenicmutationssuchasp53; 6) confer
the same arresting and cell killing effects in drug resistant cells, i.e.,
when other chemotherapeutic drug fails; and 7) absorbed readily or
secreted by cells at its original bioactive form.
The viral protein R (Vpr) made by the human immunodefi-
ciency virus type 1 (HIV-1) could potentially fulfill many of the
aforementioned criteria. Because, 1) Vpr blocks proliferation of
cancerous cells by induction of cell cycle G2 arrest [1,2], and this
arresting effect is independent of the classic DNA checkpoints
[3,4]; 2) Vpr induces apoptosis through multiple pathways that do
not depend upon host cellular responses [5,6]; and 3) Vpr
selectively kills fast growing cells in a p53-independent manner
[7,8], suggesting Vpr-induced cell death may offer more selectively
power in killing cancerous cells than normal cells and this
cytotoxic property should be effective in many of the cancers, in
which p53 gene is mutated. 4) Vpr itself is not infectious; 5) Vpr is
a soluble protein that is also naturally transduced. The protein’s
natural tranducing ability allows it to be up taken and secreted by
cells without the aid of any special delivery vehicle [9]; and 6) Vpr
is a virion-associated protein. This allows possible delivery of the
Vpr protein to target specific tumors such as neuroblastoma or
glioma using specially designed viral vectors [For reviews, see
[10]].
HIV-1 Vpr is a small accessory viral protein with an average
length of 96 amino acids and a calculated molecular weight of
12.7 kD. Vpr is a unique protein that shows no known homology
to any other current cellular proteins. A tertiary structure of Vpr
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a-helix domain in the amino-terminal half between amino acids 17
to 46 and a long a-helix from amino acids 53 to 78 in the
carboxyl-terminal half [11]. These three a-helices are folded
around a hydrophobic core in a structure that allows interaction
between Vpr and other different cellular proteins [12]. The
interactions between Vpr and cellular proteins underline the
multifaceted roles in its interference with host cellular functions as
described above [For reviews, see [8,13,14]].
One of the most difficult cancers to treat is neuroblastoma. This
deadly sarcoma consists of malignant neuroblast cells that either
appears in the autonomic nervous system or in the adrenal
medulla. Neuroblastoma is considered a type of neuroepithelial
tumor that mainly affects infants and children up to 10 years of
age. It is one of the most common solid tumors of early childhood.
The tumor typically originates in the adrenal medulla, with the
most common site being the abdomen (near the adrenal gland) but
it can also be found in the skin, chest, neck, pelvis, or other areas.
While it is understood that genetic mutations either during fetal
development or those that have been inherited lead to neuroblas-
toma, the exact cause of these genetic mutations are still unknown.
Treatment options that are available primarily include surgery,
chemotherapy, radiation therapy, and bone marrow transplants.
However, despite various therapy options, the morbidity of this
cancer is still very high and is currently close to 100%. The
primary reason for such high morbidity is because most patients
have widespread disease at diagnosis and these tumors develop
rapid resistance to chemotherapy and radiation therapy.
A primary approach for cancer treatment often involves
chemotherapy. Chemotherapy acts by killing rapidly divided cells,
which is a main property of cancer cells. Unfortunately,
neuroblastoma develops resistance rapidly to chemotherapy agents
and makes treatment difficult. There are several possible reasons
for chemotherapy resistance, they include 1) cells that are not
killed by chemotherapy mutate and become resistant, 2) proteins
that transport drugs into cancerous cells stop working, 3) cells may
begin to pump drugs out of the cell as fast as they can enter the
cell, 4) genes that trigger an overproduction of proteins that render
a drug ineffective may become amplified, and 5) cancerous cells
may begin to repair DNA breaks caused from treatment.
Considering rapid drug resistance of neuroblastoma and a limited
numbers of drugs currently available for the treatment of
neuroblastoma, there is a great need for a new therapy that could
continue eliminating malignant cells when those cells developed
resistance to other anticancer drugs. A possible new solution to this
dilemma is the potential use of HIV-1 Vpr with its unique
biological features described above.
To demonstrate the potential utility of Vpr as an anti-cancer
agent, we have carried out proof-of-concept preliminary studies in
vitro and in vivo. Results of our studies showed that Vpr induces cell
cycle G2 arrest and apoptosis in a large variety of cancer types. We
have further demonstrated that the same Vpr effects can also be
detected in cancer cells that are resistant to anti-cancer drugs such
as DOX. Furthermore, we have adopted a neuroblastoma mouse
model system that allows us to show the suppressive effect of Vpr
on tumor growth in vivo.
Results
Vpr induces cell cycle G2 arrest in various cancerous cells
Vpr has been observed to induce cell cycle G2 arrest in a broad
assortment of eukaryotic cells ranging from fission yeast to human
cells [15,16]. These observations are suggestive that highly
conserved cellular activities in eukaryotic cells are indeed affected
by Vpr. In this study, the adenoviral infection system was selected
to measure the potential effect of HIV-1 on cell cycle G2 induction
in various cancer types (Table 1) as we described previously [17–
19]. The adenoviral systems allows for nearly 100% of cells to be
infected by transduction and detection of Vpr effects are able to be
observed as early as 5 hours [18]. Using this system, we tested the
potential effect of Vpr on various types of cancer cell lines. These
cancer types include cervical (HeLa), breast (MCF-7), ovarian
(A2780), and T- or B-cell lymphomas (Jurkat and SU-DHL-4). As
shown in Figure 1 and Table 1, Vpr induced cell cycle G2 arrest in
all cancer cell types tested with the exception that only partial G2
shift was observed in the MCF-7 cells (Figure 1 - middle). The
functional relevance of this partial G2 induction is surmised in
discussion. In addition, this G2 induction appears to be
independent of p53 gene status, which is consistent with a number
of previous reports [7,20].
Vpr induces cell cycle G2 arrest and cell death regardless
of drug resistance status to doxorubicin
Doxorubicin (Adriamycin, hydroxydaunorubicin, DOX) is an
anticancer drug that has been used in treating a wide range of
cancers, including breast, stomach, lung, ovarian and bladder
cancers as well as leukemia, many types of carcinoma, and soft
tissue sarcomas. The precise molecular mechanism of DOX has
not been well established. However, it is known to intercalate
DNA and interrupt DNA replication thus leading to cell death
[21]. Even though DOX continues to be an essential component
of first-line anti-cancer therapies in treating many types of tumors,
development of tumor drug resistant to DOX and other
anticancer regimens is a major obstacle for achieving successful
anti-cancer treatments [22,23]. To explore whether Vpr can block
cell proliferation by G2 arrest and kill those anti-cancer drug-
resistant tumor cells, we expressed the vpr gene via Adv-Vpr
transduction in three pairs of drug naı ¨ve (WT) and DOX-resistant
(DOX-R) cancer cells. They are human neuroblastoma (SK-N-
SH), osteosarcoma (SaOS2), and breast adenocarcinoma (MCF-7).
These DOX-resistant cell lines were generated by continuous
incubation of parental cell lines with stepwise increases of DOX
concentrations ranging from 10
29 to 10
26 M over a period of 3 to
6 months. Detailed method for generating these DOX-resistant
cell lines have been described previously [24]. As shown in Table 1,
expression of Vpr causes cell growth arrest in all cells tested
regardless of the drug resistant status to DOX. Moreover,
measurement of cell proliferation and viability by the MTT assay,
which metabolizes tetrazolium salt (MTT), showed little cell
proliferation or viable cells left 5 days after Adv-Vpr transduction
(Figure 2); similarly, determination of cell membrane integrity by
trypan blue, which stains only dead cells, indicated that Vpr
confers very potent cytotoxicity to those cells (Figure 2).
Vpr induces dose-dependent cell death and apoptosis in
DOX-naı ¨ve and resistant neuroblastoma cells
To further understand Vpr-induced cell killing in drug naı ¨ve
and resistant tumor cells and to prepare for an in vivo study of the
potential Vpr’s effect on tumor growth in a mouse model, we
decided to focus our study effort on neuroblastoma. Neuroblas-
toma was chosen as a model system because neuroblastoma is one
of the most common solid tumors of early childhood usually found
in babies or young children. Another reason for choosing the
neuroblastoma model is that the human neuroblastoma xenograft
mouse model system is well established [25,26].
Before conducting in vivo mouse studies, we first determined the
potential dose-dependent responses of Vpr-induced cell killing in
Vpr in Resistant Neuroblastoma
PLoS ONE | www.plosone.org 2 July 2010 | Volume 5 | Issue 7 | e11466both wild type (WT) and drug resistant (DOX-R) SK-N-SH
neuroblastoma cells. The trypan blue and the MTT assays were
used to measure cell proliferation and viability 5 days after Adv
control and Adv-Vpr transductions. Summary of these results are
shown in Figure 3A–a. While the increase of multiplicity of
infectivity (MOI) of Adv control did not cause significant cell
death, a clear dose-dependent cell killing was shown in both the
WT and DOX-R cells as indicated by the trypan blue assay. At
low end, MOI 1.0 caused about 40–80% cell death; whereas all of
the cells (100%) were killed by MOI 10.0. The MTT assay showed
the corresponding dose-dependent decrease of cell proliferation
and survival of cells, and the Western blot analyses confirmed that
Vpr was produced in those Adv-Vpr-infected cells (Figure 3A–b).
To further understand the dynamics of Vpr’s effect on cell
proliferation, cell proliferation and viability was measured over
time (up to 5 days) with MOI 2.5. As shown in Figure 3B, mock or
Adv-infected cells showed normal cell proliferation and reached a
plateau after 3 days with little or no cell proliferation detected in
Adv-Vpr infected cells. The reduced metabolic activity over time
suggested increased cell death over time. To further evaluate the
mode of Vpr-induced cell killing in neuroblastoma cells (whether
or not Vpr kills those cells by apoptosis or other mechanism)
potential caspase-3 cleavage effect was measured as an indication
of apoptosis. To distinguish Vpr-induced cell death from its effect
on cell cycle, a Vpr mutant (F34I) that causes G2 induction but
does not induce cell death was also included in this study as a
control [18,27,28]. After adenoviral infection, status of caspase-3
was monitored starting from 6 to 36 hours by Western blot
analysis using antibodies against total caspase-3 (Figure 3C, top
lane) or specifically cleaved caspase-3 (Figure 3C - middle lane).
No caspase-3 cleavage was detected in the Adv-F34I Vpr-infected
cells (indicated by ‘‘m’’) over the entire test period; the caspase-3
cleavage was clearly seen from 24–36 hours in cells that were
infected with the wild type (indicated by ‘‘w’’) Vpr.
Together, results of these in vitro studies support the idea that
Vpr blocks neuroblastoma cell proliferation by cell cycle G2 arrest
and cell killing via apoptosis. More importantly, Vpr confers these
cytotoxic effects to neuroblastoma cells at a comparable level
regardless of their drug resistance status.
In vivo effect of Vpr on neuroblastoma tumor growth in a
mouse model system
We next examined the Vpr effect on tumor growth of
neuroblastoma cells in the C57-SCID mouse model system
[29,30]. Two different approaches were used to introduce Vpr
into tumors, i.e., pre- viral transduction prior to cell inoculation
into mice or post-intratumoral injection. For pre-transduction,
wild type and DOX-resistant SK-N-SH were injected with Adv,
Adv-VprF34I and Adv-Vpr s.c. in the left flank of C57-SCID mice.
The tumor size was measured every 7 days. Final tumor size
measurement was at 26 days post-transduction and mice were
then sacrificed for further analysis. As shown in Figure 4A, an
average tumor size of approx. 2 cm was clearly seen in mice that
were inoculated with WT or DOX-resistant SK-N-SH cells 26
days post-transduction. Similar tumor sizes were also observed in
Ad-F34Ivpr infected mice. In contrast, very small nodules at the
site of injection were seen in the Ad-Vpr-transduced mice,
suggesting expression of Vpr in those cells prevented their growth
Table 1. Quantitative summary of Vpr-induced G2 arrest in various cancer types.
Cell Line Cancer Type P53 Status Treatment G2 Arrest Reference
HeLa Cervical Cancer Null Adv (2) [44,45]
Adv-Vpr (+)
SK-N-SH (WT) Neuroblastoma Wt Adv (2) [46]
Adv-Vpr (+)
Adv-F34IVpr** (+)
SK-N-SH (DOX-R) Adv (2)
Adv-Vpr (+)
Adv-F34IVpr** (+)
MCF-7* (WT) Breast Cancer Wt Adv (2) [33,47]
Adv-Vpr (+/2)
MCF-7 (DOX-R) Adv (2)
Adv-Vpr (+/2)
SaOS-2 (WT) Osterosarcoma Null Adv (2) [48]
Adv-Vpr (+)
SaOS-2 (DOX-R) Adv (2)
Adv-Vpr (+/2)
A2780 Ovarian Cancer Wt Adv (2) [49]
Adv-Vpr (+)
SU-DHL-4 B-Cell Lymphoma Mutant Adv (2) [50,51]
Adv-Vpr (+)
Jurkat T-Cell Lymphoma Null Adv (2) [52,53]
Adv-Vpr (+)
Note: *, PP2A is mutated [33,34]; **, F34IVpr causes cell cycle G2 shift but no cycling arrest [18,27,28]; WT, wild type; DOX-R, doxorubicin-resistant; G2 arrest: (+), strong
G2 arrest; (2), no G2 arrest, (+/2), attenuated G2.
doi:10.1371/journal.pone.0011466.t001
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mice, individual mice were injected with all three transducing
viruses s.c. at the abdominal area as shown in Figure 4B. Similar to
what we have observed in mice inoculated with single treatment,
about equal size of tumors were seen at the sites of Adv or Adv-
F34Ivpr injections whereas little or no nodules were seen at the
sites of Adv-Vpr injections.
One of the potential arguments about the results generated
from pre-transduction is that expression of Vpr in situ could
rapidly kill the SK-N-SH cells thus preventing tumor formation
and thus testing of the Vpr effect on actual tumor growth. To
circumvent this issue, an alternative post-intratumoral injection
method was used. The WT and DOX-R SK-N-SH neuroblas-
toma cells were prepared and inoculated essentially the same way
as described above. The Adv, Adv-Vpr or Adv-F34Ivpr was then
injected discretely 3-times into the tumors 2 weeks after cell
inoculation. The tumor size was measured every 7 days. Final
measurement of tumor size was at 39 days post-injection and
mice were then sacrificed for further analysis. Statistic tests were
carried out to evaluate potential differences in tumor size each
week or during the entire experimental period. The final results
are presented in Table 2. Even though Vpr reduced 44.1611.8%
of the tumor growth in the wild type SK-N-SH tumors by week 1
after intratumoral injection, statistical analyses indicated a t-value
of 2.35 (p=0.10), i.e., no statistical difference; similarly, no tumor
growth difference was seen in the Dox-R tumors at week 1.
However, statistic significant differences were observed both in
the wild type and Dox-R tumors by week 2 and week 3. In
particular, in the WT neuroblastoma cells, Vpr reduced
64.266.7% or 76.465.9% of the tumor growth by week 2 or 3
after intratumoral injection, respectively; similarly, a comparable
percent of reduction (67.164.5% or 75.661.8%) was also
detected in the DOX-R cells in the same time period.
Comparison of the tumor growth during the entire experimental
period by using the weighted average sums [31] suggested overall
differences in tumor growth between the Ad control-treated mice
and Ad-Vpr injected mice (p,0.05). In contrary, no statistic
differences were found between the Ad control and Ad-F34IVpr
groups. Therefore, it is clear that expression of Vpr in tumors has
significantly reduced the tumor growth and expression of Vpr
Figure 2. Expression of Vpr leads to cell death in a variety of
wide type (WT) and doxorubicin (DOX)-resistant cancer cells as
indicated. Three pairs of drug naı ¨ve (WT) and DOX-resistant (DOX-R)
cancer cells were tested for Vpr-induced G2 arrest (Table 1) and cell
death. These cancer cell lines were grown as described in the Materials
and Methods. Cells were transduced with Adv or Adv-Vpr with MOI of
2.5. Cell viability was determined either by the Trypan Blue exclusion
assay, which identifies dead cells (top figure) or by the MTT assay to
measure cell survival (bottom figure). Cells were examined 5 days p.i.
Intials: WT, wildtype; Dox-R, doxorubicin-resistant; 1, Mock; 2, Adv and
3, Adv-Vpr.
doi:10.1371/journal.pone.0011466.g002
Figure 1. Vpr induces cell cycle G2 arrest in various cancer cell
types. All cancer cell lines (see Table 1 for details; only 3 cell lines are
shown here as examples) were grown as described in the Materials and
Methods. Cells were transduced with Adv or Adv-Vpr with MOI of 1.0.
The cells were harvested 48 hrs post-infection (p.i.), Cells were then
prepared as described in Materials and Methods. Cellular DNA content
was analyzed by FACScan flow cytometry (Becton Dickinson) as we
previously described [4,19]. The cell cycle profiles were modeled using
ModFit software (Verity Software House, Inc.).
doi:10.1371/journal.pone.0011466.g001
Vpr in Resistant Neuroblastoma
PLoS ONE | www.plosone.org 4 July 2010 | Volume 5 | Issue 7 | e11466Figure 3. Vpr induces cell death and apoptosis in DOX-naı ¨ve and resistant SK-N-SH cells. A. Vpr induces dose-dependent cell death in
drug-naı ¨ve and resistant SK-N-SH cells. a. Level of Vpr-induced cell death was examined by infecting DOX-naı ¨ve and resistant SK-N-SH cells using
increasing MOI of Adv or Adv-Vpr viruses. Cell death was measured by determining the cell membrane integrity and proliferation using Trypan blue
straining (left) or cell viability by the MTT assay (right). Cells proliferation and viability were examined 5 days p.i. b. Vpr protein production was
Vpr in Resistant Neuroblastoma
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regardless of its drug resistant status.
Discussion
In the present study, we demonstrated that a HIV-1 viral
protein Vpr blocks cell proliferation by arresting those cells in G2
phase of the cell cycle in various cancer cell types tested (Table 1;
Figure 1). In addition, Vpr induces cell death in three of those
cancer cell lines regardless whether they are resistant or sensitive to
DOX (Figure 2). Further analyses of the Vpr effect on
neuroblastoma cells indicated that Vpr induces cell death in a
dose-dependent manner (Figure 3A–B) via apoptosis as indicated
by caspase-3 cleavage (Figure 3C). By using a neuroblastoma
mouse model, we have further demonstrated that delivery of Vpr
via adenoviral delivery to neuroblastoma tumors, either by pre-
infection (Figure 4A–B) and intratumoral injection (Figure 4C),
markedly inhibited tumor growth. Thus the described results
demonstrate by proof-of-concept that Vpr might be a good
candidate for further investigation on its role in tumor suppression
especially in those that are resistant to anticancer drugs.
Even though Vpr induces cell cycle G2 arrest in all of the cancer
cell types tested, it was noticed that the level of G2 arrested cells in
the breast cancer cell line MCF-7 was much reduced (Figure 1 -
middle). It is unclear at the moment why this cell line is partially
resistant to Vpr-induced G2 arrest. However, there does appear to
be an interesting correlation between Vpr-induced G2 arrest and
the enzymatic status of protein phosphatase 2A (PP2A). As we
have reported previously, one of the unique features of Vpr-
induced G2 arrest is that it requires the function of PP2A
[2,4,16,32]. Search of literature indicated that the A regulatory
subunit of PP2A is either significantly reduced or lost in the MCF-
7 cell line [33,34]. The reduction of G2 arrest in MCF-7 cells
supported the notion that Vpr inhibits cell proliferation by
induction of G2 arrest through a PP2A-mediated mechanism
[4,32]. Furthermore, this observation suggests that Vpr may not be
able to block cell proliferation by G2 arrest in all tumor cells,
especially those tumor cells that contain PP2A-related mutations.
Further investigation of this notion is certainly warranted
especially in the context of using Vpr as an anti-cancer agent.
Vpr induces cell death and apoptosis through multiple
mechanisms [For reviews, see [5,6]]. Since Vpr is able to induce
cell death and apoptosis in both DOX-naı ¨ve and resistant
neuroblastoma cells, one or few of those proposed Vpr pathways
may have caused the observed cytotoxicity. Our future effort will
focus on testing which mechanism of Vpr-induced cell death could
overcome apoptotic resistance, a typical feature of many cancerous
cells including neuroblastoma. Based on data shown in Figure 3C,
it is clear that Vpr is able to cause apoptosis as indicated by the
caspase-3 cleavage. This observation is consistent with our
characterization of Vpr-induced apoptosis in the same neuroblas-
toma cells shown by using the Annex V assay [35]. There, we have
further demonstrated that Vpr-induced apoptosis in the SK-N-SH
neuroblastoma cells through a mitochondria-dependent and
caspase-9-mediated mechanism [35].
We used pre-infection and intra-tumoral injections in our
mouse model for the introduction of Vpr into neuroblastoma
tumors. These two methods were used because expression of Vpr
in situ could rapidly kill cells and thus prevent testing on actual
tumor growth. Our results demonstrated both methods signifi-
cantly reduced tumor growth after introduction of Vpr. Compa-
rably, DOX-resistant cells also demonstrated similar level of tumor
size reduction supporting the premise that Vpr expression
suppresses tumor growth regardless of drug resistant status.
It is worthwhile to mentioning that, in the described
experiments, we did not test the potential Vpr effect on metastatic
neuroblastoma cells. We did, however, carry out preliminary
pharmacological studies to test potential adverse effect of C57-
SCID mice when they were exposed to Vpr through systematic
full-body injection. In those experiments, an escalating increase of
Adv-Vpr viral particles ranging from 1610
13 to 6610
13 of viral
particles were injected into C57-SCID mice through tail veins. No
obvious adverse reactions were observed in those mice during the
entire experimental period. Pathologic examinations of various
organs 3 weeks after viral injection showed no clear cytotoxic
effects imposed by Vpr (data not shown). Therefore, systematic
introduction of Vpr could also be an option for future testing.
The concept of using HIV-1 Vpr as a potential anticancer agent
is not new. In fact, other early studies including ours have
suggested this possibility [36] and a number of studies have
showed that delivery of Vpr to various tumors such as melanoma
[37–39], hepatoma [40,41] and oral cancer [42] suppress tumor
growth in vivo. What is new, however, is that we have
demonstrated for the first time that Vpr is capable of suppressing
tumor growth regardless whether it is sensitive or resistant to an
anticancer drug through induction of cell cycle G2 arrest and
apoptosis. This finding could potentially be significant because
destruction of drug resistant cancer cells makes it a potential and
powerful new and alternative anti-cancer agent. This type of
anticancer agent may become particularly useful as a supplemental
viral therapeutic agent for selective inhibition of tumor growth
especially when other therapies fail.
Materials and Methods
Cell lines and culture
Various human cancer cell lines that represent different types of
cancers with or without drug resistance to the anticancer drug
doxorubicin (DOX) are used in this study and summarized in
Table 1. Unless specifically specified, these cell lines were grown in
the Dulbecco’s Modified Eagle’s Medium (DMEM) (Cellgro) or
RPMI 1640 medium (Sigma) supplemented with 10% fetal bovine
serum (FBS, Invitrogen). Incubation was at 37uC in a 5% CO2
incubator.
Adenoviral infection
Adenoviral vector (Adv) and Adenoviral vector inserted with the
vpr gene (Adv-Vpr) were kindly provided by Dr L. J. Zhao [17].
Approximately 1610
6 of the test cells were infected with Adv or
Adv-Vpr viruses. Forty-eight hours p.i., cells were harvested for cell
cycle analysis or Western blot analysis. Infections were performed
at a multiplicity of infection (MOI) of 1.0 for cell cycle analyses as
shown in Table 1 and Fig. 1. MOI of 2.5 was used for initial cell
death analyses as shown in Fig. 2.Under this adenoviral
transducing condition, greater than 90% infection efficiency was
achieved with these viral stocks (data not shown).
confirmed by Western blot analysis. Note that it is very difficult to detect Vpr protein at low MOI. Successful infection of Adv-Vpr was verified by
enlarged nuclei of cells as previously reported [43]. B. Vpr induces cell death over time in drug- naı ¨ve and resistant SK-N-SH cells. Both drug-naı ¨ve and
resistant SK-N-SH cells treated the same way as A. Only MOI2.5 was used here. C. Vpr induces apoptosis in drug-naı ¨ve and resistant SK-N-SH cells.
Caspase-3 cleavage was monitored up to 36 hours. Initials: Csp3, caspase-3; cl-Csp3, cleaved caspase-3; m, Adv-VprF34I; w, Adv-Vpr.
doi:10.1371/journal.pone.0011466.g003
Vpr in Resistant Neuroblastoma
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Thecellswereharvested 48 hrsp.i.,then washedtwice using2 ml
5 mM EDTA/PBS and centrifuged at 1,500 rpm. Following
centrifugation, cells were re-suspended in 1 ml 5 mM EDTA/
PBS and fixed with 2.5 ml of 95–100% cold ethanol. Fixed cells
were then stored overnight at 4uC. Following storage, cells were
again centrifuged and washed twice with 2 ml 5 mM EDTA/PBS
and centrifuged again at 1,500 rpm. After re-suspension in 0.5 ml
PBS, cells were incubated with RNase A (10 mg/ml) at 37uC for 30
minutes and then at 0uC with propidium iodine (PI, 10 mg/ml) for
1 hour. Cells were then filtered and DNA content was analyzed by
FACScan flow cytometry (Becton Dickinson). The cell cycle profiles
were modeled using ModFit software (Verity Software House, Inc.).
Western blot analysis
Cells were lysed with lysis buffer (50 mM Tris, pH 7.5, 150 mM
NaCl, 2 mM EDTA, 1% Triton X-100) for 30 minutes while on
ice. Cells were then centrifuged at 13,000 rpm for 1 minute to
remove debris. Protein concentrations recovered in the superna-
tants were measured using BCA protein assay kit (Pierce). After
boiling, 50 mg of protein was loaded into Criterion Precast Gels
(BioRad) for electrophoresis separation. Proteins were then
transferred to Trans-blotH Nitrocellulose membranes and blocked
with 5% skim milk in TBST buffer (10 mM Tris, pH 8.0,
150 mM NaCl, 0.1% Tween 20) for 1 hour at room temperature.
Primary antibodies were applied overnight at 4uC. After washing 3
times in TBST for 10 minutes each time, the membranes were
then incubated with secondary antibody for 1 hour at room
temperature. Antibodies used included rabbit polyclonal anti-Vpr
[custom generated through the Proteintech Group, Inc (Chicago,
IL)], rabbit polyclonal anti-caspase 3 (Cell Signaling and rabbit
polyclonal anti-cleaved-caspase 3 (Asp175) (Cell Signaling) anti-
bodies. After incubation with secondary antibody, membranes
were washed again and proteins were detected with SupersignalH
West Dura Extended Duration Substrate (Pierce, Rockford, IL).
Figure 4. Vpr suppresses tumor regression in a neuroblastoma mouse model. Suppression of neuroblastoma tumor growth by Vpr is
demonstrated here either by pre-transduction of Adv-Vpr (A-B) or post-intratumoral injection (C). For pre-transduction, wild type (WT) or DOX-resistant
SK-N-SH were grown in DMEM supplemented with 10% FBS at 37uC with a 95%Air/5%CO2 atmosphere. Fresh cells were first grown in a 12-well plate for
36 hours andadenoviral transduction was carried out5 hours before cell inoculation withMOIof2.5,which was determined empirically. Cells were then
treated with Trpsin- EDTA, re-suspended in DMEM and washed with PBS 3 times. Final cells were suspended in DMEM for inoculation. About 2610
6 cells
in the volume of 100 ml were injected s.c. in the left flank of C57-SCID mice. 3–4 mice were injected for each treatment. These treatment groups include
an Adv viral control, Adv-Vpr and Adv-F34IVpr. The F34IVpr mutant was used here as a control since a single amino acid change of amino acid 34 from
Phenylalanine(F) toIsoleucine(I)rendersVprunabletocauseapoptosis (Figure3C)but allowsforthecellcycletoenteraprolongedG2phase[18,27,28].
The tumor size was measured every 7 days by measuring two perpendicular tumor diameters using calipers. Final tumor measurement was at 26 days
post-transduction and mice were then sacrificed for further analysis. For intra-lesional injection of Vpr, the WT and DOX-R SK-N-SH neuroblastoma cells
were prepared essentially the same way as described above. 200 ml of the Adv, Adv-Vpr or Adv-F34Ivpr was then injected discretely 3-times into the
tumors 2 weeks after cell inoculationwith a viral concentrationof 1,012/ml. Thetumor size was measuredevery 7 days. Final measurement of tumor size
was at 39 days post-injection and mice were then sacrificed for further analysis. Three independent experiments were carried out and results of these
experiments with average tumor size with standard deviation (SD) are presented in Table 2.
doi:10.1371/journal.pone.0011466.g004
Table 2. Summary of Vpr-induced tumor regression of WT and DOX-resistant neuroblastoma in C57-SCID mice.
SK-N-SH
Tumor size in
mm (WT)
Tumor size in
mm (DOX-R)
Average±SD
Size increase
(%± SD)
Reduction by
Vpr (%± SD) Average±SD
Size increase
(%± SD)
Reduction by Vpr
(%± SD)
Week 0
Ad 983.3615.3 n.a. n.a. 983.365.8 n.a. n.a.
Ad-Vpr 973.3±15.3 n.a. n.a. 986.7±5.8 n.a. n.a.
Ad-F34IVpr 980626.5 n.a. n.a. 983.3611.6 n.a. n.a.
Week 1
Ad 1331.36121.3 35.8614.4 n.a. 1217.7624.8 23.862.3 n.a.
Ad-Vpr 1156.7±51.3 18.8±4.6 44.1±11.8 1226±54.8 24.3±5.2 21.4±15.0
Ad-F34IVpr 13706147.3 39.9615.3 12.8617.0 1220685.4 24.067.4 22.1633.9
Week 2
Ad 2032.36101 106.8 n.a. 2218.76105.1 125.7611.4 n.a.
Ad-Vpr 1340±52.9 27.6±3.7 64.2±6.7** 1393.3±63.5 41.2±5.6 67.1±4.5**
Ad-F34IVpr 19406103.9 98.1613.4 7.7612.1 2210695.4 119.965.1 4.566.8
Week 3
Ad 3671.36651.4 273.6668.0 n.a. 35606262.9 262.1627.6 n.a.
Ad-Vpr 1576.7±6.4 62.0±1.9 76.4±5.9* 1616.7±77.7 63.8±7.0 75.6±1.8**
Ad-F34IVpr 3696.76784.2 278.8691.4 20.168.1 36306130 269.3617.7 23.063.9
Note: Tumor sizes were measured at 39 days post-intratumoral injection (Week 0). Levels of statistical significance of the t-test results between the Adv control and the
testing groups (Ad-Vpr or Ad-F34IVpr): *, p,0.05; **, p,0.001; Weighted average sums of the t-tests [31] for both wild type and Dox-R mice showed statistic differences
at the level of p,0.05. Note: na, non-applicable.
doi:10.1371/journal.pone.0011466.t002
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Cell viability was determined by the MTT assay (Boehringer
Mannheim) following the manufacturer’s instructions. Approxi-
mately 1610
6 of the testing cancer cells were used to initiate the
experiments. On day one, cells were trypsinized and centrifuged at
500 rpm for 5 minutes. The media was then removed and cells
were re-suspended in 1 ml of complete media and a cell count per
ml was calculated. Using this cell count, cells were then diluted to
75,000 cells per ml with complete media. 100 ml of cells (7,500
cells total) were then added to each well of a 96-well plate and
incubated overnight at 37uC. On day two, cells were treated with
Adv or Adv-Vpr transduction. At the day of indicated test, 20 mlo f
5 mg/ml MTT was added to each well and incubated at 37uC for
3.5 hours. Next the media was removed, washed with PBS and
then 150 ml of MTT solvent was added to each well. The plates
were then gently agitated for 15 minutes in an orbital shaker. After
agitation, absorbance at 630 nm was measured.
Trypan blue staining
Viability of treated cells was analyzed using trypan blue stain, a
vital dye (Gibco BRL). Cells were trypsinized and centrifuged at
500 rpm for 5 minutes. The media was then removed and cells
were re-suspended in complete media. Next, cells were diluted to
an approximate cell concentration of 1610
5 to 2610
5 cells per ml
in a screw cap test tube. 0.1 ml of 0.4% trypan blue stain was then
added and the test tubes were mixed thoroughly. The cell mixture
was then allowed to stand for 5 minutes at room temperature.
After 5 minutes cell counting was performed using a hemacytom-
eter. Viable cells (no staining) and non-viable cells (stained blue)
were observed and counted under microscope.
Neuroblastoma mouse model
The human neuroblastoma xenograft mouse model system is
well established [25,26]. A reproducible mouse model for human
neuroblastoma can be achieved typically by subcutaneous (s.c.)o r
intraperitoneal (i.p.) injection of 2–5610
6 of human neuroblastoma
SK-N-SH cells into C57BL/6N (C57BL) and C57BL/6J-scid/scid
(C57-SCID) (Charles Rivers). Treatment groups include mice
injected with the adenoviral vector (Adv) control, wild type Vpr-
carrying adenovirus (Adv-Vpr) and F34I mutant Vpr-carrying
adenovirus (Adv-F34IVpr). Three mice were used in each
treatment group with a total of 9 mice in each experiment. Three
independent experiments were carried out for this study. Palpable
tumors at the injection sites developed within 3 weeks with an
average size of 2–3 cm in diameters, and tumors later metastasize
into various organs including adrenal glands, local lymph nodes,
bone, liver, skin, and bone marrow [29,30]. Histologically, the
tumors developed in mouse resembles the original metastases from
which the tumors were derived and the SK-N-SH tumor cells can
be distinguished from the in vitro cultured cells by the dopamine-b-
hydroxylase (DBH) activity [30]. The animal protocol used in this
study was approved by the Animal Care and Use Committee of
the Children’s Memorial Research Center (no. 2006-29).
Statistical Analyses
The statistic t-test was used in log scale to analyze the potential
differences in tumor sizes for each week’s measurement between
the Ad control group and the Vpr-treated groups (Ad-Vpr or Ad-
F34IVpr). To evaluate the overall impact of Vpr on tumor growth
during the entire 3 weeks, the weighted average sums of the tumor
sizes (in log scales) were compared using a related test designed
specifically for xenograft tumor models [31].
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